BTK and autoimmune disease: Although ibrutinib has not been studied clinically as a BTK inhibitor in MS, it has shown efficacy in other autoimmune diseases, such as arthritis, lupus, and recently in treatment of COVID-19 (SARS-CoV-2) (11–14).